IL6 and inflammatory bowel disease: On the other hand, the FXR agonist OCA blocked the NF-κB-mediated pro-inflammatory cytokine production, including IL-1b, IL-6, and TNF-a, in animal models of IBD and intestinal IRI [9,10].